BUY Glenmark Pharmaceuticals — Vaishali Parekh, 18 May 2026

byVaishali Parekh, Prabhudas LilladherHorizon: NA (inferred Swing (≤2wk))18 May 2026via Business Today

Entry₹2,339.9Inferred

Target₹2,600

Stop loss₹2,200-5.98% risk

Exit₹2,2001 Jun 2026, 9:35 am

Stop-loss hit-5.98%

Follow Vaishali Parekh for new calls(33% target hit, 45 closed calls)Get alerts Watch GLENMARK for new buy/sell callsGet alerts See 1 active Swing call on GLENMARK

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Sept, 5:41 am IST

2 supporting2 neutral0 opposing

Supports the BUY call (2)

Glenmark Pharmaceuticals' subsidiary, Ichnos Glenmark Innovation (IGI), has announced a new development candidate, ISB 2301. This is a first-in-class multispecific immune cells activator designed to t

NSE · Press Release·20 May · 2w ago

Glenmark Pharmaceuticals Inc., USA has launched Vancomycin Hydrochloride for Injection USP in 500mg/vial and 1 g/vial strengths.

NSE · Press Release·18 May · 2w ago

Neutral / worth noting (2)

Press Release and Management Discussion & Analysis for the Fourth Quarter ended March 31, 2026.

BSE · Company Update·29 May · 2d ago

The Board of Directors of Glenmark Pharmaceuticals Limited considered and approved audited financial results and recommended dividend.

BSE · Board Meeting·29 May · 2d ago

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

BUY Glenmark Pharmaceuticals — Vaishali Parekh, Prabhudas Lilladher

AI Assessment